Bolt Biotherapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BOLT, updated each market day.
BOLT AI Sentiment
AI sees no strong directional signal for Bolt Biotherapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Bolt Biotherapeutics, Inc. Common Stock
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Sector
Exchange
Market Cap
$8,666,267
Cap Tier
Employees
23
Headquarters
REDWOOD CITY, CA
Listed Since
Feb. 5, 2021
Website
BOLT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BOLT Volatility
Bolt Biotherapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
